Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SARS-CoV Spike antibody

This anti-SARS-CoV Spike antibody is a Mouse Monoclonal antibody detecting SARS-CoV Spike in Neut. Suitable for SARS Coronavirus (SARS-CoV).
Catalog No. ABIN7794778

Quick Overview for SARS-CoV Spike antibody (ABIN7794778)

Target

See all SARS-CoV Spike (SARS-CoV S) Antibodies
SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Reactivity

  • 51
  • 16
  • 1
SARS Coronavirus (SARS-CoV)

Host

  • 42
  • 9
  • 1
Mouse

Clonality

  • 42
  • 10
Monoclonal

Conjugate

  • 31
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This SARS-CoV Spike antibody is un-conjugated

Application

  • 26
  • 19
  • 6
  • 5
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Neutralization (Neut)

Clone

COV1-80
  • Purpose

    Anti-SARS-CoV-1, Spike (Clone COV1-80)-Purified No Carrier Protein

    Specificity

    COV1-80 targets the prefusion spike protein of SARS-CoV-1 and SARS-CoV-2. Antigen Distribution Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-80 monoclonal antibody is cross-reactive, targeting the spike protein of both SARS-CoV-1 and SARS-CoV-2. While it does not block the ACE2 receptor, COV1-80 still functions as a neutralizing antibody, meaning it can inhibit the virus's capacity to infect host cells. The exact epitope that COV1-80 binds to remains unidentified, highlighting the need for further research to understand its mechanism of action fully. Nonetheless, the demonstrated neutralizing activity of COV1-80 makes it a promising candidate for therapeutic strategies, particularly in combination therapies that target multiple viral epitopes for enhanced effectiveness.

    Purification

    Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

    Purity

    >=90 % monomer by analytical SEC and SDS-Page

    Isotype

    IgG1 lambda
  • Restrictions

    For Research Use only
  • Concentration

    1 μg/mL

    Buffer

    This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

    Preservative

    Without preservative

    Storage

    4 °C,-80 °C

    Storage Comment

    This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.
  • Target

    SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

    Alternative Name

    SARS-CoV Spike

    Target Type

    Viral Protein
You are here:
Chat with us!